Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PR negative status confers therapeutic sensitivity to Carboplatin, Gemcitabine in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of locally recurrent metastatic triple negative breast cancer.